Aprepitant

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.

Get full access to this article

View all access options for this article.

References

Emend [package literature]. Merck & Co., Inc.; March 2003.

Houn

Food and Drug Administration Approval Letter – Emend. Food and Drug Administration. March 26, 2003. http://www.fda.gov/cder/foi/appletter/2003/21549ltr.pdf. Accessed on April 9, 2003.

Tattersall

F.D.

The novel NK₁ receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.

Neuropharmacology. 2000; 39: 652–63.

Huskey

S.W.

Substance P receptor antagonist 1: Conversion of phos-phoramidate prodrug after IV administration to rats and dogs.

Drug Metab Dispos. 1999; 27: 1367–73.

Campos

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

J Clin Oncol. 2001; 19: 1759–67.

DeVane

C.L.

Substance P: A new era, a new role.

Pharmacotherapy. 2001; 21: 1061–9.

Ballard

T.M.

Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK₁ receptor antagonist.

Eur J Pharmacol. 2001; 412: 255–64.

Duffy

R.A.

Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK₁ antagonists.

J Pharmacol Exp Ther. 2002; 301: 536–42.

Kramer

M.S.

Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

Science. 1998; 281: 1640–5.

10.

Nutt

Substance-P antagonists: A new treatment for depression?

Lancet. 1998; 352: 1644–6.

11.

Della'Zanna

, Chen

W-J

, Division of Gastrointestinal and Coagulation Drug Products. Food and Drug Administration. NDA-21–549 Emend (aprepitant) background package for Advisory Committee Meeting on March 6, 2003. February 5, 2003. www.fda.gov. Accessed March 6, 2003.

12.

Hesketh

P.J.

Differential time course of cisplatin induced emesis with a 5HT₃ antagonist or an NK₁ antagonist: Rationale for combination therapy [abstract]. Proceedings of the 2002 Annual Meeting of the American Society of Clinical Oncology. 2002;abstract 1476. www.asco.org. Accessed December 6, 2002.

13.

Navari

R.M.

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist.

N Engl J Med. 1999; 340: 190–5.

14.

Chawla

S.P.

Establishing the dose of oral NK-1 antagonist MK-869 for chemotherapy induced nausea and vomiting [abstract]. Proceedings of the 2001 Annual Meeting of the American Society of Clinical Oncology. 2001;abstract 1527. www.asco.org. Accessed December 6, 2002.

15.

de Wit

Maintenance of protection against chemotherapy induced nausea and vomiting in multiple cycles with the oral NK₁ antagonist MK-0869 [abstract 1467]. Proceedings of the 2002 Annual Meeting of the American Society of Clinical Oncology; 2002. www.asco.org. Accessed December 6, 2002.

16.

Cocquyt

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

Eur J Cancer. 2001; 37: 835–42.

17.

Van Belle

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

Cancer. 2002; 94: 3032–41.

18.

Urban

L.A.

, Fox

A.J.

NK1 receptor antagonists: Are they really without effect in the pain clinic?

Trends Pharmacol Sci. 2000; 21: 462–4.